Advance Notice of Proposed Rulemaking: International Pricing Index Model for Medicare Part B Drugs
December 31, 2018
BIO strongly opposes the potential proposal detailed in the ANPRM and calls for withdrawal of the IPI model in its entirety, as:
- The IPI model is inconsistent with the charge of CMS’ Innovation Center, and does not appropriately consider benefit to the patient;
- The IPI model imports foreign price controls on American innovation, jeopardizing access to new medicines for Medicare’s vulnerable beneficiaries;
- The IPI model introduces new middlemen and complexity into providers’ delivery of critical medicines, potentially jeopardizing care to patients without reducing beneficiary costs; and
- The IPI model is part of broader Agency efforts that are eroding the value of the Medicare benefit for seniors and putting patient access to care at risk.
These concerns are described further in the balance of this comment letter.
Download Full Comments Below
We write as a coalition of advocates for the startup ecosystem to voice our strong support for the IGNITE American Innovation Act, legislation to support startups through the economic crisis by allowing companies to monetize tax assets generated…
The following letter provides BIO’s feedback on a number of regulatory proposals by the Centers for Medicare & Medicaid Services that would ease barriers to use of value-based purchasing arrangements within Medicaid and commercial plans, broaden…
The Biotechnology Innovation Organization (“BIO”) would like to submit the following comments regarding FDA’s recent proposal to implement aspects of the Canadian importation provisions of Section 804 of the Food Drug & Cosmetics Act (“FD&C…